Status:

COMPLETED

Effect of Omega-3 Fatty Acid on Neurobehavioral Status of Children With Autism Spectrum Disorder: A Randomized, Double-Blind, Placebo Controlled Trial

Lead Sponsor:

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh

Conditions:

Autism Spectrum Disorder

Eligibility:

All Genders

2-18 years

Phase:

PHASE2

Brief Summary

This study is conducted to assess whether Omega-3 fatty acid improves neurobehavioral staus of children with Autism Spectrum Disorder and whether there is any correlation of this improvement with refe...

Detailed Description

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder of children with lifelong impacts. WHO estimates the international prevalence of ASD in 2022 at 1 in 100 children. Till date, no...

Eligibility Criteria

Inclusion

  • Fulfills diagnosis of ASD by meeting DSM-5 diagnostic criteria. Written parental consent for participation. Age of children: 2-18 years. Sex: all.
  • \-

Exclusion

  • Those taking Omega-3 fatty acid or fish oil at present. Known allergy to fish or fish oil. Diagnosed with a psychotic disorder (e.g. Schizophrenia) or mood disorder, including depression or bipolar disorder.

Key Trial Info

Start Date :

September 19 2023

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 5 2024

Estimated Enrollment :

64 Patients enrolled

Trial Details

Trial ID

NCT06125782

Start Date

September 19 2023

End Date

February 5 2024

Last Update

July 9 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

BSMMU

Dhaka, Bangladesh, 1000